
WHAT IS CLAIMED IS:

1. Use of a compound having the structure:



in the manufacture of a medicament for treating relapsed or refractory chronic lymphocytic leukemia (CLL) or relapsed or refractory small lymphocytic lymphoma (SLL), wherein the medicament is for oral administration once per day of 420 mg of the compound.

2. The use of claim 1, wherein the medicament is for administration with a second cancer treatment regimen.

3. The use of claim 2, wherein the second cancer treatment regimen comprises lenalidomide, chlorambucil, ifosphamide, doxorubicin, mesalazine, thalidomide, temsirolimus, everolimus, fludarabine, fostamatinib, paclitaxel, docetaxel, ofatumumab, rituximab, dexamethasone, prednisone, CAL-101, ibritumomab, tositumomab, bortezomib, pentostatin, endostatin, bendamustine, cyclophosphamide, endostatineverolimus, etoposide, hydroxydaunorubicin, vincristine, or a combination thereof.

4. The use of claim 1, wherein the medicament is for administration with bendamustine.

5. The use of claim 1, wherein the medicament is for administration with rituximab.

6. The use of claim 1, wherein the medicament is for administration with rituximab and bendamustine.

7. The use of claim 1, wherein the medicament is for administration with fludarabine, cyclophosphamide, and rituximab.

8. The use of claim 1, wherein the medicament is for administration with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab.

9. The use of any of claims 1-8, wherein the relapsed or refractory CLL is high risk relapsed or refractory chronic lymphocytic leukemia.

10. The use of any of claims 1-9, wherein the relapsed or refractory CLL is characterized by a nucleic acid deletion in chromosome 17 or chromosome 11.

11. The use of claim 10, wherein the deletion is in 17p.


12. The use of claim 10, wherein the deletion is in 17p13.

13. The use of claim 10, wherein the deletion is in 11q.

14. The use of claim 10 wherein the deletion is in 11q22.


15. The use of claim 1, wherein the medicament is in the form of a solid oral dosage form.

16. Use of a compound having the structure:



in the manufacture of a medicament for the treatment of mantle cell lymphoma in an individual who has already received at least one prior therapy for mantle cell lymphoma, wherein the medicament is for oral administration once per day of 560 mg of the compound.

17. Use of a compound having the structure:



in the manufacture of a medicament for the treatment of Waldenström's macroglobulinemia in an individual who has already received at least one prior therapy for Waldenström's macroglobulinemia, wherein the medicament is for oral administration once per day of 420 mg of the compound.

18. The use of any one of claims 1-17, wherein, following administration of the compound, the individual achieves a stable disease, a partial response, or a complete response.

19. The use of any one of claims 1-17, wherein, following administration of the compound, the individual achieves a partial response or a complete response.

20. The use of any one of claims 1-17, wherein, following administration of the compound, the individual achieves a complete response.

21. The use of any one of claims 1-17, wherein, following administration of the compound, the individual does not experience a progressive disease.